Added to YB: 2026-08-31
Pitch date: 2026-08-28
HIK.L [bullish]
Hikma Pharmaceuticals PLC
Author Info
AP Research is an independent cross-asset research platform focused on global macro, thematic investing and portfolio construction. Sign up for the newsletter.
Company Info
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products.
Market Cap
GBP 4.7B
Pitch Price
N/A
Price Target
N/A
Dividend
3.77%
EV/EBITDA
7.16
P/E
12.68
EV/Sales
1.86
Sector
Pharmaceuticals
Category
growth
UK Primer: The Equity Revival - Hikma Pharmaceuticals PLC
HIK.L: Hikma combines defensive healthcare demand with meaningful growth potential as the largest pharmaceutical company by sales across its MENA markets and the third-largest US generic-injectables supplier by volume. Its 118-product Injectables pipeline, including 15 ready-to-use formulations, plus investment in complex inhalation products and expanded manufacturing capacity could provide catalysts, while modest 2026 guidance is followed by analyst expectations for profit-growth acceleration in 2027-28.
Read full article (1 min)